Bryan P Bednarz
Overview
Explore the profile of Bryan P Bednarz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jollota S, Bergeron D, Verkouteren R, Nour S, Fitzgerald R, Kwon O, et al.
Appl Radiat Isot
. 2025 Feb;
218:111683.
PMID: 39892031
Autoradiography is an important tool in preclinical investigations with alpha-emitting radionuclides. Precise biodistribution studies establish the effectiveness of biological "targeting" strategies, assuring that the promise of targeted alpha therapy (TAT)...
2.
Kerr C, Jin W, Liu P, Grudzinski J, Ferreira C, Rojas H, et al.
bioRxiv
. 2025 Jan;
PMID: 39763914
Radiopharmaceutical therapy (RPT) enhances tumor response to immune checkpoint inhibitors (ICI) in preclinical models, but the effects of different radioisotopes have not been thoroughly compared. To evaluate mechanisms of response...
3.
Sa A, Barateiro A, Bednarz B, Almeida P, Vaz P, Madaleno T
Front Oncol
. 2024 Aug;
14:1449082.
PMID: 39148904
[This corrects the article DOI: 10.3389/fonc.2022.879167.].
4.
Kerr C, Sheehan-Klenk J, Grudzinski J, Adam D, Nguyen T, Ferreira C, et al.
bioRxiv
. 2024 Jul;
PMID: 39071353
Teaser: This study describes the time course and nature of tumor immunomodulation by radiopharmaceuticals with differing physical properties.
5.
Kwon O, Hoffman S, Ellison P, Bednarz B
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001411
Radiopharmaceutical therapy (RPT) is evolving as a promising strategy for treating cancer. As interest grows in short-range particles, like Auger electrons, understanding the dose-response relationship at the deoxyribonucleic acid (DNA)...
6.
Adam D, Grudzinski J, Marsh I, Hill P, Cho S, Bradshaw T, et al.
Int J Radiat Oncol Biol Phys
. 2024 Feb;
119(4):1275-1284.
PMID: 38367914
Purpose: Targeted radiopharmaceutical therapy (RPT) in combination with external beam radiation therapy (EBRT) shows promise as a method to increase tumor control and mitigate potential high-grade toxicities associated with re-treatment...
7.
Sodji Q, Forsberg M, Cappabianca D, Kerr C, Sarko L, Shea A, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201618
Chimeric antigen receptor (CAR) T cells have been relatively ineffective against solid tumors. Low-dose radiation which can be delivered to multiple sites of metastases by targeted radionuclide therapy (TRT) can...
8.
Sa A, Barateiro A, Bednarz B, Almeida P, Vaz P, Madaleno T
Front Oncol
. 2023 Oct;
13:1293922.
PMID: 37876973
[This corrects the article DOI: 10.3389/fonc.2022.879167.].
9.
Allen K, Kwon O, Hutcheson M, Grudzinski J, Cain S, Cruz F, et al.
Pharmaceuticals (Basel)
. 2023 Jul;
16(7).
PMID: 37513891
Background: Osteosarcoma (OS) represents the most common primary bone tumor in humans and in companion dogs, being practically phenotypically identical. There is a need for effective treatments to extend the...
10.
Adam D, Hammer C, Malyshev J, Culberson W, Bradshaw T, Grudzinski J, et al.
Biomed Phys Eng Express
. 2023 Apr;
9(4).
PMID: 37084718
Voxel-level dosimetry based on nuclear medicine images offers patient-specific personalization of radiopharmaceutical therapy (RPT) treatments. Clinical evidence is emerging demonstrating improvements in treatment precision in patients when voxel-level dosimetry is...